ArticleBMC infectious diseases2025
Assessment of some hematological and inflammatory parameters among patients with active pulmonary tuberculosis in Ibb governorate, Yemen.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActive pulmonary tuberculosis (PTB) is a highly prevalent chronic infectious disease and one of the most worldwide health problems, especially in our country “Yemen”. This study aimed to evaluate certain hematological and inflammatory parameters in patients with active pulmonary tuberculosis (PTB) before and after treatment in Ibb governorate, Yemen. SUBJECTS AND
methodsThe study collected 100 blood and serum samples from active PTB patients, diagnosed using Ziehl-Neelsen staining for acid-fast bacilli, culture on Löwenstein-Jensen medium, tuberculin skin test and chest radiography, supervised by a specialist physician. These samples were analyzed for various hematological and inflammatory parameters before initiating standard anti-TB treatment and again at two, four and six months post-treatment.
resultsThe findings indicated changes in hematological parameters: Hemoglobin (Hb) levels were increased from 11.00 ± 1.41 g/dl before treatment to 11.95 ± 1.32, 13.08 ± 1.04, and 14.21 ± 0.96 after two, four, and six months of treatment, respectively. The total white blood cell count (Total WBCs) before treatment was 11,172 ± 2656.53, which decreased to 8903 ± 2026.31, 6650 ± 1336.47 and 5229 ± 591.40/mm3 after two, four and six months of treatment. Additionally, inflammatory parameters were showed a significant decrease: erythrocyte sedimentation rate (ESR) was dropped from 95.43 ± 21.98 mm/hr before treatment to 10.53 ± 6.65 mm/hr after 6 months and C-reactive protein (CRP) levels were decreased from 41.04 ± 12.08 mg/L before treatment to 0.24 ± 1.18 mg/L after 6 months. Moreover, the study demonstrated that hematological parameters (Hb increased, Total WBCs decreased) and inflammatory parameters were normalized in PTB patients after anti-TB treatment in Ibb governorate, Yemen.
conclusionThese parameters gradually normalized after treatment with anti-TB drugs, suggesting their potential use in the diagnosis and monitoring of treatment efficacy in active PTB patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.